3698 Haven Ave
10 articles about Synthego
Synthego Announces Invalidation of Agilent Patents in CRISPR Dispute
Synthego Corp. has announced a victory in its dispute with Agilent Technologies, Inc., regarding two of Agilent's patents which have been invalidated by a ruling of the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.
Synthego Opens State-of-the-Art GMP Guide RNA Manufacturing Facility to Enable CRISPR Genomic Medicines
Synthego Corp., a leading provider of genome engineering solutions, announced the opening of its state-of-the-art GMP synthesis facility.
Synthego Introduces CRISPR Discovery Partners to Streamline CRISPR-Driven Drug Discovery Research
Synthego Corp. announced the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services.
The 7th Annual CAR-TCR Summit is ongoing in Boston, with more than 1,000 experts in CAR and TCR technologies attending. Here’s a look at some of the latest research and data being presented.
Synthego Launches Engineered Cell Libraries to Validate Targets with Speed and Accelerate Drug Discovery
Synthego, the genome engineering company, announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by providing arrayed CRISPR-edited cells for direct use in functional screening assays.
Synthego Expands Capabilities of Halo Platform with Next-Generation Manufacturing Facility
Synthego, the genome engineering company, announced that the company has broken ground on a 20,000-square-foot manufacturing facility designed to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year.
Money on the Move: February 16–22
2/23/2022More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.
BioSpace Movers & Shakers, Feb. 18
2/18/2022Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic
Synthego, the genome engineering company, today announced it has raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors.
The company plans to use the monies raised to create a cell and gene therapy discovery and development ecosystem researchers can use to speed their research.